2019 AAN Fall Conference Exhibit and Onsite Information by American Academy of Neurology

Exhibit and On-site Information FEATURING: October 17 Advanced Practice Provider Pre-conference

Fall Conference: October 18-20

The Cosmopolitan of Las Vegas

AAN.com/view/FCLinks

#AANFC

RESOURCES Information in this guide is also available at AAN.com/view/FCLinks. WiFi Access WiFi throughout the conference: • Network: Meeting-Cosmopolitan • Password (case-sensitive): neurology AAN Conferences Mobile App Download the AAN Conferences Mobile App at AAN.com/view/MobileApp to view: • Program schedule and speakers • Program materials • Program evaluations for claiming CME • Exhibitors • Attendees • Meal times, locations, and menus To log in to the app: • Username: Your AAN ID, located on the front of your badge • Password: Your confirmation number, located on the back of your badge (begins with a capital letter) The AAN Conferences Mobile App is sponsored by Kyowa Kirin, Inc.

Audience Response System Some programs will use Audience Response System to seek input from attendees real time. Programs using this interactive feature are noted within the program schedule. Audience Response System is available at AAN.cnf.io (also within the mobile app). #AANFC 1

PROGRAM MATERIALS AND CLAIMING CME • Program materials (e.g., slides) are available online (AAN.com/view/syllabi)

and in the AAN Conferences Mobile App. Updated content will be available by October 25 and will be available for approximately one year post-conference. • To claim CME hours, attendees must complete program evaluations in the AAN Conferences Mobile App or at AAN.com/view/CME by November 4, 2019, after the attendee has been verified on-site as eligible for credit and attended the program. Transcripts will be available approximately six to eight weeks following the close of the conference. AAN members can also access their transcript via NeuroTracker™ at AAN.com/view/NeuroTracker. • Non-physicians participating in this program will receive an acknowledgement of participation indicating attendance at an activity designated for AMA PRA Category 1 Credit(s)™.

EXHIBIT HALL: BELMONT 2 & 3 Get information on the latest products and services from the neurologic community to assist with practice management and patient care. Complimentary lunch and coffee breaks will be provided to registered attendees. The Exhibit Hall is located in Belmont 2 & 3. Exhibit Hall Hours: Friday, October 18 • 11:30 a.m.–1:00 p.m. • 2:30 p.m.–3:00 p.m. • 4:00 p.m.–6:00 p.m.

Lunch Break Opening Reception

Saturday, October 19 • 9:30 a.m.–10:00 a.m. Break • 11:30 a.m.–1:00 p.m. Lunch

EXHIBIT HALL PASSPORT & PRIZES Use your Exhibit Hall Passport (provided at registration desk), to visit a world of exhibitors and enter drawings to win an iPad, Nest Indoor Camera, $250 Amazon gift card, and AAN membership. See the Exhibit Hall Passport for the official rules. Apple, Amazon, and Nest are not participants in or sponsors of this promotion. 2

2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

Connect with the AAN CONNECT WITH THE AMERICAN ACADEMY OF NEUROLOGY Stop by the official AAN booths in the Belmont Ballroom foyer during Exhibit Hall hours to learn more about what the AAN has to offer. The American Academy of Neurology is here to help you succeed! Stop by to speak to AAN staff about becoming a member, renewing your membership, updating your profile and publication preferences, applying for the prestigious FAAN membership status, or for general questions about all the incomparable benefits of AAN membership. Looking for opportunities to achieve quality improvement objectives or demonstrate the quality of your care? Visit the Axon Registry® booth to learn how to participate in this Qualified Clinical Data Registry – free to US AAN members – and how it can help your neurology practice or institution. The Neurology Career Center is the world’s largest neurology-specific job board. Visit the Career Center to post a neurology opening or to search hundreds of jobs nationwide.

#AANFC 3

Credits, Disclosures, & Policies The American Academy of Neurology Institute (AANI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The AANI holds Accreditation with Commendation, the ACCME highest level of recognition for a CME provider.

AMA CREDIT DESIGNATION The AANI designates this live activity for a maximum of (*) AMA PRA Category 1 Credit(s)â&#x201E;˘. Physicians should claim only the credit commensurate with the extent of their participation in the activity. *See individual program descriptions for the maximum number of credits per program.

ABPN STATEMENT The American Board of Psychiatry and Neurology has reviewed the AAN conference and has approved this program as a part of a comprehensive lifelong learning program, which is mandated by the ABMS as a necessary component of continuing certification.

FACULTY DISCLOSURE OF COMMERCIAL RELATIONSHIPS Consistent with the AAN/AANI and ACCME policies, faculty must disclose any relevant financial relationship with the manufacturer(s) discussed in their presentation, so that learners may form their own judgments about material discussed during the educational activity. Full disclosure of facultyâ&#x20AC;&#x2122;s commercial relationships will appear in the individual program materials and in the AAN Conferences Mobile App.

UNLABELED USE DISCLOSURE The AANI requires all faculty members to disclose if a product is not labeled for the use being discussed or that the product is still investigational. Such disclosures will appear in the individual program materials.

2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

ANTI-HARASSMENT The AAN is committed to providing a conference environment that is free from all forms of discrimination and harassment. The Meetings Anti-Harassment Policy promotes the AAN’s values by defining the expectations for all participants at any AAN conference and related social events. Violations of this Policy may be reported to Member Services at (800) 879-1960, memberservices@aan.com, or to Academy staff on-site.

CONSENT TO AAN USE OF IMAGES All portions of AAN conferences may be photographed, videotaped, or recorded for future rebroadcast, distribution, promotion, or other commercial purpose. By attending the conference, you are consenting to being recorded, photographed, and videotaped without acknowledgment, payment, or remuneration of any kind. Any recordings, photographs, or videos of any nature are the sole property of AAN and its successors and assignees.

SOCIAL MEDIA, PHOTOGRAPHY, AND VIDEOGRAPHY – REGIONAL CONFERENCES The American Academy of Neurology (AAN) encourages all AAN Regional Conference attendees to share their Regional Conference experience on social media using #AANFC for the Fall Conference. When doing so, please adhere to the following AAN Regional Conference Social Media Policies: Photography and videography are permitted* for personal use only if captured via mobile phone, handheld device, or self-contained camera (no external lighting, tripod, or microphone) in hallways. Photography and videography intended for commercial use is strictly prohibited. Live streaming is prohibited in all areas of an AAN Regional Conference. Photography and videography are prohibited for all conference attendees in the following locations: • Exhibit Hall • Programming Sessions The AAN has the right to ask any Fall Conference attendee to remove a social post or to stop taking photos or recording video at any time.

#AANFC 5

Thursday, October 17 8:00 a.m.–6:00 p.m.

Advanced Practice Provider Pre-Conference

Mont Royal 1

Audience Response System: AAN.cnf.io Program Director(s):

Robert D. Brown, Jr., MD, FAAN, Rochester, MN Calli Leighann Cook, DNP, APRN, FNP-C, Atlanta, GA

8:00 a.m.–8:15 a.m.

Welcome and Program Overview

CME

7.5

Robert D. Brown, Jr., MD, FAAN, Rochester, MN Calli Leighann Cook, DNP, APRN, FNP-C, Atlanta, GA James C. Stevens, MD, FAAN, Fort Wayne, IN 8:15 a.m.–9:15 a.m.

Localizing the Lesion: Clinical Correlations of Neuroanatomy Part 1: Neuroanatomy Basics and Localizing the Lesion Jaffar Khan, MD, FAAN, Atlanta, GA

9:15 a.m.–9:25 a.m.

Break

9:25 a.m.–10:25 a.m.

Localizing the Lesion: Clinical Correlations of Neuroanatomy Part 2: Applied Neuroanatomy: Clinical Correlations Jaffar Khan, MD, FAAN, Atlanta, GA

10:25 a.m.–10:45 a.m. Break 10:45 a.m.–11:15 a.m. Neurodiagnostic Studies: The Use and Interpretation of Neuroimaging and Neurophysiology Techniques in Clinical Practice: Neuroimaging Joseph C. Masdeu, MD, PhD, FAAN, Houston, TX 11:15 a.m.–11:20 a.m. Stretch Break 11:20 a.m.–11:50 a.m. Neurodiagnostic Studies: The Use and Interpretation of Neuroimaging and Neurophysiology Techniques in Clinical Practice: Neurophysiology (EMG) Miriam L. Freimer, MD, FAAN, Columbus, OH 11:50 a.m.–11:55 a.m. Stretch Break 11:55 a.m.–12:30 p.m. Neurodiagnostic Studies: The Use and Interpretation of Neuroimaging and Neurophysiology Techniques in Clinical Practice: Neurophysiology (EEG) Elaine C. Wirrell, MD, FAAN, Rochester, MN

2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

12:30 p.m.–1:30 p.m.

Lunch

1:30 p.m.–2:40 p.m.

Common Topics in Clinical Neurology: Headache Calli Leighann Cook, DNP, APRN, FNP-C, Atlanta, GA Rashmi B. Halker Singh, MD, FAAN, Scottsdale, AZ

2:40 p.m.–2:50 p.m.

Break

2:50 p.m.–4:00 p.m.

Common Topics in Clinical Neurology: Spine Disorders and Radiculopathy J. D. Bartleson, MD, FAAN, The Villages, FL

4:00 p.m.–4:10 p.m.

Break

4:10 p.m.–5:20 p.m.

Common Topics in Clinical Neurology: Multiple Sclerosis Michelle Fabian, MD, New York, NY Bryan D. Walker, PA, Durham, NC

5:20 p.m.–5:30 p.m.

Wrap Up Robert D. Brown, Jr., MD, FAAN, Rochester, MN Calli Leighann Cook, DNP, APRN, FNP-C, Atlanta, GA

5:30 p.m.–6:00 p.m.

Networking Event

The American Academy of Neurology would like to thank Allergan, Inc. for support of the Advanced Practice Provider Pre-conference.

#AANFC 7

Friday, October 18 8:00 a.m.–9:30 a.m.

Neurology Update 1: Headache and Neuro-ophthalmology Belmont 1 & 5 Program Director(s):

Nancy J. Newman, MD, FAAN, Atlanta, GA Neeraj Kumar, MD, Rochester, MN

CME

1.5

Program directors will be the same for all Neurology Update programs. 8:00 a.m.–8:45 a.m.

Headache Stephanie J. Nahas, MD, FAAN, Philadelphia, PA

8:45 a.m.–9:30 a.m.

Neuro-ophthalmology Valerie Biousse, MD, Atlanta, GA

Practice Management 1: 2019 Coding Updates: E/M, Prolonged Care Codes, and Telehealth Mont Royal 1 Audience Response System: AAN.cnf.io Program Director(s):

Brad C. Klein, MD, MBA, FAAN, Willow Grove, PA

CME

1.5

Program director will be the same for all Practice Management programs. 8:00 a.m.–8:05 a.m.

Introduction Brad C. Klein, MD, MBA, FAAN, Willow Grove, PA

8:05 a.m.–8:40 a.m.

2019 Coding Updates: Part 1 Jeffrey Waugh, MD, PhD, Dallas, TX

8:40 a.m.–9:15 a.m.

2019 Coding Updates: Part 2 Raissa Villanueva, MD, FAAN, Rochester, NY

9:15 a.m.–9:30 a.m.

Questions and Answers Faculty

Neuroimaging for the General Neurologist

Nolita 1-2

Program Director(s):

Joshua P. Klein, MD, PhD, FANA, FAAN, Boston, MA

8:00 a.m.–9:30 a.m.

Neuroimaging for the General Neurologist Joshua P. Klein, MD, PhD, FANA, FAAN, Boston, MA

CME

1.5

9:30 a.m.–10:00 a.m.

Break

Course Rooms Foyer

2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

10:00 a.m.–11:30 a.m.

Neurology Update 2: Neuro-oncology and Neurogenetics

Belmont 1 & 5 CME

1.5 10:00 a.m.–10:45 a.m.

Neuro-oncology Amy A. Pruitt, MD, FAAN, Philadelphia, PA

10:45 a.m.–11:30 a.m.

Neurogenetics Brent L. Fogel, MD, PhD, FAAN, Los Angeles, CA

Neuroscience in the Clinic: Traumatic Brain Injury Program Director(s):

Renee M. Pazdan, MD, FAAN, Aurora, CO

10:00 a.m.–10:05 a.m.

Introduction Renee M. Pazdan, MD, FAAN, Aurora, CO

10:05 a.m.–10:30 a.m.

Domestic Violence and TBI Glynnis Zieman, MD, Phoenix, AZ

10:30 a.m.–10:55 a.m.

Military and Veteran TBI Alicia Souvignier, Captain, Fort Carson, CO

10:55 a.m.–11:20 a.m.

Mild TBI/Concussion Erik John Beltran, MD, Lincolnshire, IL

11:20 a.m.–11:30 a.m.

Questions and Answers Faculty

Nolita 1-2 CME

1.5

Practice Management 2: Improving Patient Access and Engagement Is Good for Business Mont Royal 1 Audience Response System: AAN.cnf.io

CME

1.5

10:00 a.m.–10:05 a.m.

Introduction Brad C. Klein, MD, MBA, FAAN, Willow Grove, PA

10:05 a.m.–10:40 a.m.

Leveraging Technology and Communication Techniques to Improve Patient Engagement Radhika Sampat, DO, Canton, GA

10:40 a.m.–11:15 a.m.

Using Patient Engagement as a Business Tool J. Todd Barnes, MBA, Oklahoma City, OK

11:15 a.m.–11:30 a.m.

Questions and Answers Faculty

#AANFC 9

Friday, October 18 11:30 a.m.–1:00 p.m.

Lunch in Exhibit Hall

Belmont 2 & 3

1:00 p.m.–2:30 p.m.

Neurology Update 3: Dementia and Movement Disorders

Belmont 1 & 5 CME

1.5 1:00 p.m.–1:45 p.m.

Dementia Jonathan Graff-Radford, MD, Rochester, MN

1:45 p.m.–2:30 p.m.

Movement Disorders Vicki Shanker, MD, New York, NY

Practice Management 3: Managing Cost of Care: Why It Matters and What You Should Do Mont Royal 1 Audience Response System: AAN.cnf.io 1:00 p.m.–1:05 p.m.

Introduction Brad C. Klein, MD, MBA, FAAN, Willow Grove, PA

1:05 p.m.–1:40 p.m.

Framing the Healthcare Cost Crisis Lyell K. Jones, MD, FAAN, Rochester, MN

1:40 p.m.–2:15 p.m.

Managing Cost of Care in Your Practice Joseph V. Fritz, PhD, Amherst, NY

2:15 p.m.–2:30 p.m.

Questions and Answers Faculty

Update on Medical Management of Stroke Program Director(s):

Amy K. Guzik, MD, Winston Salem, NC

1:00 p.m.–1:15 p.m.

Introduction and Overview Amy K. Guzik, MD, Winston Salem, NC

1:15 p.m.–1:45 p.m.

Medical Management Updates 1 Sherita Chapman, MD, Charlottesville, VA

1:45 p.m.–2:15 p.m.

Medical Management Updates 2 Amy K. Guzik, MD, Winston Salem, NC

2:15 p.m.–2:30 p.m.

Questions and Answers Faculty

10 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

CME

1.5

Nolita 1-2 CME

1.5

2:30 p.m.–3:00 p.m.

Break in Exhibit Hall

Belmont 2 & 3

3:00 p.m.–4:30 p.m.

Neurology Update 4: Multiple Sclerosis and Autoimmune Neurology

Belmont 1 & 5 CME

1.5 3:00 p.m.–3:45 p.m.

Multiple Sclerosis Aaron E. Miller, MD, FAAN, New York, NY

3:45 p.m.–4:30 p.m.

Autoimmune Neurology Eoin P. Flanagan, MBBCh, Rochester, MN

Controversies in Neurology Plenary Session

Nolita 1-2

Program Director(s):

Paul M. George, MD, PhD, MSE, Stanford, CA

3:00 p.m.–4:30 p.m.

Should Ambulances Bypass Primary Stroke Centers for Comprehensive Stroke Centers? Johanna Therese Fifi, MD, New York, NY Kori Sauser Zachrison, MD, MSc, FACEP, Boston, MA

Practice Management 4: Transitioning Your Practice into a Value-based Model

CME

1.5

Mont Royal 1 CME

Audience Response System: AAN.cnf.io

1.5

3:00 p.m.–3:40 p.m.

Infrastructure and Care Delivery Essentials for APM Success David A. Evans, MBA, Dallas, TX

3:40 p.m.–4:20 p.m.

Being a Provider in the Era of Alternative Payment Models Robert M. Kropp, MD, FAAN, Saint Petersburg, FL

4:20 p.m.–4:30 p.m.

Questions and Answers Faculty

4:00 p.m.–6:00 p.m.

Exhibit Hall Opening Reception

Belmont 2 & 3

Sponsored by:

#AANFC 11

Saturday, October 19 8:00 a.m.–9:30 a.m.

Neurology Update 5: Autonomic Disorders and Epilepsy

Belmont 1 & 5 CME

1.5 8:00 a.m.–8:45 a.m.

Autonomic Disorders Roy L. Freeman, MD, Boston, MA

8:45 a.m.–9:30 a.m.

Epilepsy Jacqueline French, MD, FAAN, New York, NY

Contemporary Concerns About Brain Death Determination

Nolita 1-2

Audience Response System: AAN.cnf.io Program Director(s):

Ariane Lewis, MD, New York, NY

8:00 a.m.–8:35 a.m.

Medical and Legal Criteria for Brain Death Around the World Ariane Lewis, MD, New York, NY

8:35 a.m.–9:00 a.m.

Brain Death and Society: Familial Objections to Use of Neurologic Criteria to Declare Death Matthew Kirschen, MD, PhD, Philadelphia, PA

9:00 a.m.–9:20 a.m.

The Brain Death Working Group James A. Russell, DO, FAAN, Manchester, MA

9:20 a.m.–9:30 a.m.

Questions and Answers Faculty

CME

1.5

Practice Management 5: Running an Efficient Organization Mont Royal 2 Audience Response System: AAN.cnf.io 8:00 a.m.–8:05 a.m.

Introduction Brad C. Klein, MD, MBA, FAAN, Willow Grove, PA

8:05 a.m.–8:40 a.m.

Best Practices of Efficient Medical Organizations Catherine Annulli, Middlebury, CT

8:40 a.m.–9:15 a.m.

Running an Efficient Organization Part 2 Joseph V. Fritz, PhD, Amherst, NY

9:15 a.m.–9:30 a.m.

Questions and Answers Faculty

12 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

CME

1.5

9:30 a.m.–10:00 a.m.

Break in Exhibit Hall

Belmont 2 & 3

10:00 a.m.–11:30 a.m.

Neurology Update 6: Neuromuscular Disease 1 and 2

Belmont 1 & 5 CME

1.5 10:00 a.m.–10:45 a.m.

Neuromuscular Disease 1: Anterior Horn Cell, Plexus, and Peripheral Nerve Jonathan D. Glass, MD, Atlanta, GA

10:45 a.m.–11:30 a.m.

Neuromuscular Disease 2: Neuromuscular Junction and Muscle Lyell K. Jones, MD, FAAN, Rochester, MN

Neuroscience in the Clinic: Headache

Nolita 1-2

Program Director(s):

Dawn C. Buse, PhD, San Diego, CA

10:00 a.m.–10:05 a.m.

Introduction and Objectives Dawn C. Buse, PhD, San Diego, CA

10:05 a.m.–10:25 a.m.

Overview of Migraine and Psychiatric Co-morbidity Epidemiology and Their Shared Pathophysiology; Overview of Migraine Criteria, Depression Criteria, and Anxiety Criteria Mia T. Minen, MD, New York, NY

10:25 a.m.–10:35 a.m.

Overview of Assessment of Psychiatric Co-morbidity and Migrainerelated Disability Dawn C. Buse, PhD, San Diego, CA

10:35 a.m.–11:05 a.m.

Clinical Management of Migraine and Psychiatric Co-morbidities Noah Rosen, MD, Great Neck, NY

11:05 a.m.–11:20 a.m.

Behavioral Management of Migraine and Psychiatric Co-morbidities, Review of Empirically Supported Treatments, How to Make Successful Referrals, and How and Where to Find Providers Dawn C. Buse, PhD, San Diego, CA

11:20 a.m.–11:30 a.m.

Questions and Answers/Panel Discussion Faculty

CME

1.5

#AANFC 13

Saturday, October 19 10:00 a.m.–11:30 a.m. continued

Practice Management 6: Building a Team Approach in Small- and Medium-sized Practices Mont Royal 1 CME

Audience Response System: AAN.cnf.io

1.5

10:00 a.m.–10:05 a.m.

Introduction Brad C. Klein, MD, MBA, FAAN, Willow Grove, PA

10:05 a.m.–10:40 a.m.

Investing in Your Patients and Practice with APPs Seth A. Lefberg, Somerset, NJ

10:40 a.m.–11:15 a.m.

How APPs Can Support Growth Strategies and Enhance Patientcentered Care Pnina Mintz, PhD, Voorhees, NJ

11:15 a.m.–11:30 a.m.

Questions and Answers Faculty

11:30 a.m.–1:00 p.m.

Lunch in Exhibit Hall

Belmont 2 & 3

1:00 p.m.–2:30 p.m.

Contemporary Clinical Issues Plenary Session

Nolita 1-2

Moderator:

Paul M. George, MD, PhD, MSE, Stanford, CA

1:00 p.m.–1:30 p.m.

AFM: Beyond Acute and Flaccid Teri Schreiner, MD, MPH, Aurora, CO

1:30 p.m.–2:00 p.m.

Amyloid PET Leads to Frequent Changes in Management of Cognitively Impaired Patients: The Imaging Dementia–Evidence for Amyloid Scanning (IDEAS) Study Rachel Whitmer, PhD, Oakland, CA

2:00 p.m.–2:30 p.m.

Advances in the Acute Treatment of Migraine Jessica Ailani, MD, Mclean, VA

14 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

CME

1.5

1:00 p.m.–2:30 p.m. continued

Practice Management 7: Private Practice Sustainability Through an Expanded Services Model Audience Response System: AAN.cnf.io

Mont Royal 2 CME

1.5

1:00 p.m.–1:40 p.m.

Revenue Diversification Strategies: How Can Ancillary Services Boost Revenues and Improve Patient Care? Part 1 David A. Evans, MBA, Dallas, TX

1:40 p.m.–2:20 p.m.

Revenue Diversification Strategies: How Can Ancillary Services Boost Revenues and Improve Patient Care? Part 2 Leeann Garms, Raleigh, NC

2:20 p.m.–2:30 p.m.

Questions and Answers Faculty

Continuum® Test Your Knowledge: A Multiple-choice Question Review 1

Belmont 1 & 5

*CME for this program is self-assessment. Audience Response System: AAN.cnf.io Program Director(s):

Aaron E. Miller, MD, FAAN, New York, NY

1:00 p.m.–1:45 p.m.

Epilepsy Jacqueline French, MD, FAAN, New York, NY

1:45 p.m.–2:30 p.m.

Multiple Sclerosis Aaron E. Miller, MD, FAAN, New York, NY

CME

1.5

#AANFC 15

Saturday, October 19 1:00 p.m.–4:30 p.m.

Skills Workshop: Neuromuscular Ultrasound

Nolita 3

Program Director(s):

Rocio Carolina Garcia Santibanez, MD, Atlanta, GA

1:00 p.m.–1:30 p.m.

Introduction and Orientation to Neuromuscular Ultrasound Rocio Carolina Garcia Santibanez, MD, Atlanta, GA

1:30 p.m.–4:00 p.m.

Breakout 1: Upper Extremity Ultrasound Rocio Carolina Garcia Santibanez, MD, Atlanta, GA

1:30 p.m.–4:00 p.m.

Breakout 2: Lower Extremity Ultrasound Matthew Ginsberg, MD, Akron, OH

1:30 p.m.–4:00 p.m.

Breakout 3: Brachial Plexus and Muscle Jeffrey A. Strakowski, MD, Columbus, OH

4:00 p.m.–4:30 p.m.

Questions and Answers / Wrap Up Rocio Carolina Garcia Santibanez, MD, Atlanta, GA Matthew Ginsberg, MD, Akron, OH Jeffrey A. Strakowski, MD, Columbus, OH

CME

3.25

3:00 p.m.–4:30 p.m.

Continuum® Test Your Knowledge: A Multiple-choice Question Review 2

Belmont 1 & 5

*CME for this program is self-assessment Audience Response System: AAN.cnf.io Program Director(s):

Aaron E. Miller, MD, FAAN, New York, NY

3:00 p.m.–3:45 p.m.

Dementia Jonathan Graff-Radford, MD, Rochester, MN

3:45 p.m.–4:30 p.m.

Headache Stephanie J. Nahas, MD, FAAN, Philadelphia, PA

16 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

CME

1.5

3:00 p.m.–4:30 p.m. continued

Neuro-rheumatology: Neurological Manifestations of Systemic Inflammatory and Autoimmune Disease Nolita 1-2 Program Director(s):

Shamik Bhattacharyya, MD, Boston, MA

3:00 p.m.–3:30 p.m.

Neuropsychiatric Lupus Shamik Bhattacharyya, MD, Boston, MA

3:30 p.m.–4:00 p.m.

Neurosarcoidosis Kristin Marissa Galetta, MD, Boston, MA

4:00 p.m.–4:30 p.m.

Vasculitis of the Nervous System Michael John Bradshaw, MD, Billings, MT

Practice Management 8: Managing People, Managing Yourself Audience Response System: AAN.cnf.io 3:00 p.m.–3:05 p.m.

Introduction Brad C. Klein, MD, MBA, FAAN, Willow Grove, PA

3:05 p.m.–3:40 p.m.

Managing People, Managing Yourself Part 1 Catherine Annulli, Middlebury, CT

3:40 p.m.–4:15 p.m.

Managing People, Managing Yourself Part 2 Rikki Nicole Maher, Lexington, KY

4:15 p.m.–4:30 p.m.

Questions and Answers Faculty

CME

1.5

Mont Royal 1 CME

1.5

5:00 p.m.–6:00 p.m.

ABPN Continuing Certification Information Session

Mont Royal 1 CME

5:00 p.m.–6:00 p.m.

ABPN Continuing Certification Information Session Jaffar Khan, MD, FAAN, Atlanta, GA ‘ Ralph F. Jozefowicz, MD, FAAN, Rochester, NY

Description: Continuing certification for diplomats of the American Board of Psychiatry and Neurology (ABPN) is sometimes overwhelming, frustrating, and misunderstood. Through this presentation, attendees will receive guidance on how to navigate continuing certification in a way that satisfies requirements and is professionally rewarding. The Continuing Certification program is a program of the American Board of Psychiatry and Neurology as mandated by the American Board of Medical Specialties. For information about your individual requirements, please contact the ABPN at (847) 229-6500 or ABPN.com.

#AANFC 17

Sunday, October 20 7:30 a.m.–9:00 a.m.

Neurology Update 7: Sleep and Neuro-infectious Disease

Nolita 1-2 CME

1.5 7:30 a.m.–8:15 a.m.

Sleep Logan D. Schneider, MD, Palo Alto, CA

8:15 a.m.–9:00 a.m.

Neuro-infectious Disease Allen J. Aksamit, Jr., MD, FAAN, Rochester, MN

Multiple Sclerosis in the Trenches: Controversy and Consensus in Clinical Decision-making Nolita 3 Audience Response System: AAN.cnf.io Program Director(s):

Aaron E. Miller, MD, FAAN, New York, NY

7:30 a.m.–7:35 a.m.

Introduction Aaron E. Miller, MD, FAAN, New York, NY

7:35 a.m.–9:00 a.m.

Discussion of Brief Case Vignettes Aaron E. Miller, MD, FAAN, New York, NY Michelle Fabian, MD, New York, NY

CME

1.5

9:00 a.m.–9:15 a.m.

Break

Course Rooms Foyer

9:15 a.m.–10:45 a.m.

Neurology Update 8: Stroke and Critical Care

Nolita 1-2 CME

1.5 9:15 a.m.–10:00 a.m.

Stroke Amie W. Hsia, MD, Washington, DC

10:00 a.m.–10:45 a.m.

Critical Care Thomas P. Bleck, MD, FAAN, Chicago, IL

18 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

9:15 a.m.–10:45 a.m. continued

Clinical EEG

Nolita 3

Program Director(s):

Katherine H. Noe, MD, PhD, FAAN, Phoenix, AZ

9:15 a.m.–9:55 a.m.

Adult EEG: Pearls and Pitfalls Katherine H. Noe, MD, PhD, FAAN, Phoenix, AZ

9:55 a.m.–10:00 a.m.

Questions and Answers Katherine H. Noe, MD, PhD, FAAN, Phoenix, AZ

10:00 a.m.–10:40 a.m.

Pediatric EEG: Pearls and Pitfalls Lily Wong-Kisiel, MD, FAAN, Rochester, MN

10:40 a.m.–10:45 a.m.

Questions and Answers Lily Wong-Kisiel, MD, FAAN, Rochester, MN

CME

1.5

The American Academy of Neurology would like to thank the following organizations for their support of the 2019 Fall Conference: • Eisai, Inc. • Grifols USA • Kronus, Inc. • Mitsubishi Tanabe Pharma America • Supernus Pharmaceuticals, Inc. • UCB, Inc. #AANFC 19

AAN Fall Conference Exhibit

104 106 108 110 112

114

118

100

200 202 204 300

207

211 213 215 217 219

306

310 312 314 316 318

302

401 405

407

409

413

20 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

417

t Hall: Belmont 2 & 3

132 134

225 227 229 231 233 235 237 324 326 328 330 332 334 336 Career Fair Neighborhood

340 342 341 437 435

Entrance

#AANFC 21

Exhibitors AbbVie, Inc.

Booth

312

1 North Waukegan Rd North Chicago, IL 60064-6329 AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader.

ACADIA Pharmaceuticals Inc.

Booth

213

ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in neurological and related central nervous system disorders.

Booth

Alexion Pharmaceuticals

204

1900 Powell Street, Suite 750 Emeryville, MA 94608 adamaspharma.com At Adamas Pharmaceuticals, Inc., we believe in the power and promise of medicines derived from our deep understanding of time-dependent biology. We strive to create medicines with therapeutic profiles that match the pattern of disease to drive a more significant and durable clinical effect

Allergan, Inc.

Booth

114

Booth

318

2525 Dupont Dr Irvine, CA 92612-1599 allergan.com Allergan plc (NYSE: AGN), is a bold, global pharmaceutical company focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world. For more information, visit Allergan’s website at www.Allergan.com.

Alliance Family of Companies

306

22 Boston Wharf Road Boston, MA 02210 ionispharma.com

Booth

104

Booth

134

4545 Fuller Drive, Suite 100 Irving, TX 75038

Alnylam Pharmaceuticals Akcea Therapeutics

Booth

121 Seaport Blvd Boston, MA 02210

3611 Valley Centre Drive, Suite 300 San Diego, CA 92130 acadia-pharm.com

Adamas Pharmaceuticals

company headquartered in Boston, Massachusetts focused on developing and commercializing drugs to treat patients with serious and rare diseases. Akcea is commercializing TEGSEDI® (inotersen) in the US, EU, and Canada, and WAYLIVRA® (volanesorsen) in the EU. Akcea is advancing a mature pipeline of novel drugs, all with the potential to treat multiple diseases. More info is available at www.akceatx.com.

535 N 1330 E. Lehi, UT 84043 alnylam.com

Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. is a biopharmaceutical

22 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

Amneal

Booth

310

400 Crossing Blvd Bridgewater, NJ 08807 amneal.com Amneal Pharmaceuticals (NYSE: AMRX) develops, manufactures and distributes generic, brand and biosimilar products. Amneal’s growing portfolio of branded pharmaceuticals is focused on central nervous system disorders, endocrinology and parasitic infections. For more information, visit amneal.com.

Atrium Health

Booth

233

1000 Blythe Blvd Charlotte, NC 28203 joinatriumhealth.org Atrium Health, one of the nation’s leading and most innovative healthcare organizations, provides a full spectrum of healthcare and wellness programs throughout North Carolina, South Carolina and Georgia. Its diverse network of care locations includes academic medical centers, hospitals, freestanding emergency departments, physician practices, surgical and rehabilitation centers, home health agencies, nursing homes and behavioral health centers, as well as hospice and palliative care services. Atrium Health works to enhance the overall health and wellbeing of its communities through high quality patient care, education and research programs, and numerous collaborative partnerships and initiatives.

Exhibit Hall Passport Destination

Barrow Neurological Institute

Booth

435

350 W. Thomas Rd Phoenix, AZ 85013 barrowneuro.org

Ranked #11 by US News & World Report for neurology and neurosurgery, Barrow Neurological Institute at Dignity Health St. Joseph’s Hospital and Medical Center in Phoenix, AZ is an internationally renowned medical center that is triple certified by JCAHO in traumatic brain injury, spinal cord injury, and stroke. Barrow Neurological Institute is also CARF-accredited in neurorehabilitation, is a NeuroNext clinical trial site, offers Phase 0 clinical trials for brain tumors, and has more neuro-science trained nurses than any hospital in the world. Barrow is committed to clinical excellence, research, outreach, and support for patients and families affected by neurological conditions and or disease. www.BarrowNeuro.org

Bausch Health

Booth

202

400 Somerset Corporate Blvd Bridgewater, NJ 08807 bausch.com Bausch + Lomb, a Bausch Health Companies Inc. company, is a leading global eye health organization that is solely focused on helping people see better to live better. Its core businesses include over-the-counter products, dietary supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care products, ophthalmic surgical devices and instruments. Bausch + Lomb develops, manufactures and markets one of the most comprehensive product portfolios in the industry, which is available in more than 100 countries. For more information, visit www.bausch.com

#AANFC 23

For more information, visit NourianzHCP.com/differentpath

Indication

Important Safety Information

NOURIANZ™ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes.

Warnings and Precautions

Dyskinesia: NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either NOURIANZ 20 mg or 40 mg discontinued treatment because of dyskinesia, compared to 0% for placebo. Hallucinations / Psychotic Behavior: Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ. Impulse Control / Compulsive Behaviors: Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson’s disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with NOURIANZ 40 mg was reported to have impulse control disorder, compared to no patient on NOURIANZ 20 mg or placebo. Please see following page for additional Important Safety Information. Please see Brief Summary of full Prescribing Information on the following pages.

EXPLORE

A DIFFERENT PATH NOW APPROVED The first and only adenosine A2A receptor antagonist for Parkinson’s disease (PD)1 NOURIANZ™ (istradefylline) is an adenosine receptor antagonist indicated as adjunctive treatment to levodopa/carbidopa in adult patients with PD experiencing “off” episodes.

Important Safety Information (continued) Drug Interactions The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20 mg once daily. Avoid use of NOURIANZ with strong CYP3A4 inducers. Specific Populations Pregnancy: Based on animal data, may cause fetal harm. Hepatic impairment: The maximum recommended dosage of NOURIANZ in patients with moderate hepatic impairment is 20 mg once daily. Avoid use in patients with severe hepatic impairment. Adverse Reactions The most common adverse reactions with an incidence ≥5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for NOURIANZ 20 mg, 40 mg, and placebo, respectively. You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see Brief Summary of full Prescribing Information on the following pages. Reference: 1. NOURIANZ [package insert]. Kyowa Kirin, Inc., Bedminster, NJ, USA.

Brief Summary of the Prescribing Information for

NOURIANZ™ (istradefylline) tablets, for oral use 1 INDICATIONS AND USAGE NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) experiencing “off” episodes. 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information The recommended dosage of NOURIANZ is 20 mg administered orally once daily. The dosage may be increased to a maximum of 40 mg once daily, based on individual need and tolerability. Initial dose titration is not required. NOURIANZ can be taken with or without food. 2.2 Dosage Adjustment with Strong CYP 3A4 Inhibitors The maximum recommended dosage of NOURIANZ with concomitant use of strong CYP3A4 inhibitors is 20 mg once daily. 2.3 Dosing with Strong CYP 3A4 Inducers Avoid use of NOURIANZ with strong CYP3A4 inducers. 2.4 Dosage Adjustment in Patients with Hepatic Impairment The maximum recommended dosage of NOURIANZ in patients with moderate hepatic impairment (Child-Pugh B) is 20 mg once daily. Closely monitor patients with moderate hepatic impairment for adverse reactions when on NOURIANZ treatment. Avoid use of NOURIANZ in patients with severe hepatic impairment (Child-Pugh C). 2.5 Dosage Adjustment for Tobacco Smokers The recommended dosage of NOURIANZ in patients who use tobacco in amounts of 20 or more cigarettes per day (or the equivalent of another tobacco product) is 40 mg once daily.

6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of NOURIANZ was evaluated in 734 patients with Parkinson’s disease (PD) taking a stable dose of levodopa and a DOPA decarboxylase inhibitor, with or without other PD medications, in four randomized, multicenter, double-blind, placebo-controlled trials 12 weeks in duration (Studies 1, 2, 3 and 4). Of the patient population exposed to NOURIANZ, 50% were male, 32% White, 67% Asian, and the mean age was 65 years (range: 33 to 84 years). Of these patients, 356 received NOURIANZ 20 mg and 378 received NOURIANZ 40 mg. Adverse Reactions Leading to Discontinuation of Treatment The incidence of patients discontinuing for any adverse reaction was 5% for NOURIANZ 20 mg, 6% for NOURIANZ 40 mg, and 5% for placebo. The most frequently reported adverse reaction causing study discontinuation was dyskinesia. Common Adverse Reactions in Pooled Placebo-Controlled Trials Table 1 shows adverse reactions with a frequency of at least 2% in patients treated with NOURIANZ 20 mg or 40 mg once daily. The most common adverse reactions in which the frequency for NOURIANZ was at least 5%, and greater than the incidence on placebo, were dyskinesia, dizziness, constipation, nausea, hallucination, and insomnia. Table 1: Adverse Reactions with an Incidence of at Least 2% in Patients Treated with NOURIANZ, and Greater than on Placebo, in Pooled Studies 1, 2, 3, and 4 Adverse Reactions

4 CONTRAINDICATIONS None. 5 WARNINGS AND PRECAUTIONS 5.1 Dyskinesia NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In controlled clinical trials (Studies 1, 2, 3, and 4), the incidence of dyskinesia was 15% for NOURIANZ 20 mg, 17% for NOURIANZ 40 mg, and 8% for placebo, in combination with levodopa. One percent of patients treated with either NOURIANZ 20 mg or 40 mg discontinued treatment because of dyskinesia, compared to 0% for placebo. 5.2 Hallucinations/Psychotic Behavior Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ. In controlled clinical trials (Studies 1, 2, 3, and 4), the incidence of hallucinations was 2% for NOURIANZ 20 mg, 6% for NOURIANZ 40 mg, and 3% for placebo. In patients treated with NOURIANZ 40 mg, 1% discontinued because of hallucinations, compared to 0% for placebo and 0% for patients treated with NOURIANZ 20 mg. The incidence of “abnormal thinking and behavior” (paranoid ideation, delusions, confusion, mania, disorientation, aggressive behavior, agitation, or delirium) reported as an adverse reaction was 1% for NOURIANZ 20 mg, 2% for NOURIANZ 40 mg, and 1% for placebo. 5.3 Impulse Control/Compulsive Behaviors Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson’s disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In controlled clinical trials (Studies 1, 2, 3 and 4), one patient treated with NOURIANZ 40 mg was reported to have impulse control disorder, compared to no patient on placebo or NOURIANZ 20 mg. In some postmarketing cases, these urges were reported to have stopped when the dose was reduced, or the medication was discontinued. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to specifically ask patients or their caregivers about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with NOURIANZ. Consider dose reduction or discontinuation if a patient develops such urges while taking NOURIANZ. 6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: • Dyskinesia [see Warnings and Precautions (5.1)] • Hallucinations/Psychotic Behavior [see Warnings and Precautions (5.2)] • Impulse Control/Compulsive Behaviors [see Warnings and Precautions (5.3)]

NOURIANZ 20 mg/day (N=356) %

NOURIANZ 40 mg/day (N=378) %

Placebo N=426 (%)

15 3

17 6

8 4

5 4 1

6 6 2

3 5 1

2 1

6 6

3 4

Nervous system disorders Dyskinesia Dizziness Gastrointestinal disorders Constipation Nausea Diarrhea Psychiatric disorders Hallucination1 Insomnia Metabolism and nutrition disorders Decreased appetite Investigations Blood alkaline phosphatase increased Blood glucose increased Blood urea increased

Respiratory, thoracic and mediastinal disorders Upper Respiratory Tract Inflammation

Skin and subcutaneous tissue disorders Rash

Includes hallucinations, hallucinations visual, hallucinations olfactory, hallucinations somatic, hallucinations auditory.

6.2 Postmarketing Experience The following adverse reaction has been identified during post approval use of istradefylline outside of the United States. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure: increased libido.

NOURIANZ Brief Summary is continued on next page.

Continued from previous page: Brief Summary of the Prescribing Information for

NOURIANZ™ (istradefylline) tablets, for oral use 7 DRUG INTERACTIONS 7.1 Effect of Other Drugs on NOURIANZ Strong CYP3A4 Inhibitors Coadministration of NOURIANZ with a strong CYP3A4 inhibitor (ketoconazole) increased istradefylline AUCinf by 2.5-fold. Therefore, the recommended maximum dosage of NOURIANZ in patients concomitantly using strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, clarithromycin) is 20 mg once daily. Strong CYP3A4 Inducers Coadministration of NOURIANZ with a strong CYP3A4 inducer (rifampin) decreased istradefylline Cmax and AUCinf by 45% and 81%, respectively. Therefore, it is recommended to avoid use of NOURIANZ with strong CYP3A4 inducers (e.g., carbamazepine, rifampin, phenytoin, St. John’s wort). 7.2 Effect of NOURIANZ on Other Drugs CYP3A4 Substrates Coadministration of NOURIANZ 20 mg with a CYP3A4 substrate (midazolam) did not affect the CYP3A4 substrate exposure, while concomitant administration of NOURIANZ 40 mg increased the CYP3A4 substrate (atorvastatin) Cmax and AUCinf by 1.5-fold. Monitor for an increase in adverse reactions of concomitant drugs that are CYP3A4 substrates when coadministering with NOURIANZ 40 mg. P-glycoprotein (P-gp) Substrates Coadministration of NOURIANZ with a P-gp substrate (digoxin) increased the P-gp substrate Cmax and AUCinf by 33% and 21%, respectively. Monitor for an increase in adverse reactions of concomitant drugs that are P-gp substrates when coadministering with NOURIANZ. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate data on the developmental risk associated with the use of NOURIANZ in pregnant women. In animal studies, oral administration of istradefylline during pregnancy resulted in teratogenicity (increased incidences of fetal structural abnormalities, embryofetal and offspring mortality and growth deficits) at clinically relevant exposures and in the absence of maternal toxicity. The teratogenic effects of istradefylline in pregnant rabbits were substantially greater when administered in combination with levodopa/carbidopa than when administered alone. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2-4% and 15-20%, respectively. 8.2 Lactation Risk Summary There are no data on the presence of istradefylline in human milk, the effects of istradefylline on the breastfed infant, or the effects of istradefylline on milk production. Istradefylline was present in the milk of lactating rats at concentrations up to 10 times that in maternal plasma. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for NOURIANZ, and any potential adverse effects on the breastfed infant from NOURIANZ or from the underlying maternal condition. 8.3 Females and Males of Reproductive Potential Contraception Use of NOURIANZ during pregnancy is not recommended. Women of childbearing potential should be advised to use contraception during treatment with NOURIANZ. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established.

8.5 Geriatric Use No adjustment of NOURIANZ dosage is recommended on the basis of age. Of the total number of PD patients who received NOURIANZ in clinical trials, 53% were ≥65 years and 13% were ≥75 years of age. No overall differences in effectiveness were observed between these patients and younger patients. 8.6 Renal Impairment No adjustment of NOURIANZ dosage is needed in patients with mild renal impairment (estimated creatinine clearance (CrCL) by Cockcroft-Gault equation: 60-89 mL/min), moderate renal impairment (CrCL 30-59 mL/min), or severe renal impairment (CrCL 15-29 mL/min). NOURIANZ has not been evaluated in patients with end-stage renal disease (ESRD) (CrCL <15 mL/min) or ESRD requiring hemodialysis. 8.7 Hepatic Impairment No adjustment of NOURIANZ dosage is needed in patients with mild hepatic impairment (Child-Pugh Class A). In patients with moderate hepatic impairment (Child-Pugh B), the steady-state exposures (AUC0-24h) were predicted to be 3.3-fold higher than in healthy subjects, based on the estimated mean terminal half-life. Therefore, the maximum recommended dosage of NOURIANZ in patients with moderate hepatic impairment (Child-Pugh B) is 20 mg once daily. Closely monitor patients with moderate hepatic impairment for adverse events when on NOURIANZ treatment. NOURIANZ has not been studied in patients with severe hepatic impairment (Child-Pugh Class C). Avoid use of NOURIANZ in patients with severe hepatic impairment. 8.8 Tobacco Smokers Tobacco smoking decreased NOURIANZ steady-state systemic exposures by 38% to 54%, which may decrease efficacy. Therefore, the recommended NOURIANZ dosage in patients who smoke 20 or more cigarettes per day (or the equivalent amount of another tobacco product) is 40 mg once daily. 10 OVERDOSAGE 10.1 Human Experience There is limited clinical experience regarding human overdosage with NOURIANZ. In clinical trials, one patient took 6 tablets (120 mg, 3 times the maximum recommended dosage) of istradefylline with alcoholic beverages and developed hallucinations, agitation, and worsening dyskinesia. 10.2 Management of Overdose There are no known specific antidotes for NOURIANZ nor any specific treatment for istradefylline overdose. If an overdose occurs, NOURIANZ treatment should be discontinued and supportive treatment should be administered as clinically indicated. Consider the long terminal half-life of istradefylline (about 83 hours) and the possibility of multiple drug involvement. Consult a Certified Poison Control Center for up-to-date guidance and advice. Manufactured by: Kyowa Kirin, Inc. Bedminster, NJ 07921

Exhibitors Baylor Scott & White Healthcare

Booth

326

2401 S 31st St Temple, TX 76513

Baylor Scott & White Health is transforming healthcare for the Better, so that our patients and health plan members receive the high-value care they deserve when and where they need it. Our team of over 47,000 employees across more than 1,000 access points is committed to the well-being of every individual, family and community we serve. Through innovation, education and care delivery, we strive to provide an exceptional customer experience, while working to make healthcare more convenient and more affordable.

Biogen

Booth

118

225 Binney Street Cambridge, MA 02142 Biogen.com One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat (MS), has the first and only approved treatment for spinal muscular atrophy (SMA) and is at the forefront of research into new medicines for neurological and neurodegenerative conditions. Led by worldclass research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no options.

Mercy is hiring Neurologists and Neurohospitalists in St. Louis and Washington, MO. Neurohospitalist Positions:

• Block schedule (seven on, seven off) • No night-time call duties • Competitive base salary with opportunity for incentives

Outpatient Neurologist Positions: • Multispecialty adult neurology group • Emphasis on outpatient services only • Systemwide Epic EMR

All opportunities offer comprehensive benefits, relocation assistance and professional liability coverage. For more information, please contact: Lisa Hauck, MBA |Senior Physician Recruiter p 314.364.3840 | f 314.364.2597 Lisa.Hauck @mercy.net | mercy.net EEO: AA/Minorities/Females/Disabled/Veterans

Your life is our life’s work.

Biogen

Booth

409

225 Binney Street Cambridge, MA 02142 Biogen.com

Booth

407

Booth

110

Booth

211

400 Beale Street, #909 San Francisco, CA 94105 catalystpharma.com

CNS Vital Signs

Booth

112

Booth

417

3140 Polaris Ave, Suite 8 Las Vegas, NV 89102 nano-ions.com

One of the pioneers in biotechnology, Biogen today has the leading portfolio of medicines to treat (MS), has the first and only approved treatment for spinal muscular atrophy (SMA) and is at the forefront of research into new medicines for neurological and neurodegenerative conditions. Led by worldclass research and development, Biogen uses novel science and leading-edge technologies to create, commercialize, and manufacture transformative therapies for patients with few or no options.

Catalyst Pharmaceuticals

Expo Enterprise

Genentech

1 DNA Way South San Francisco, CA 94080-4918 gene.com Considered the founder of the industry, Genentech, now a member of the Roche Group, has been delivering on the promise of biotechnology for over 35 years. At Genentech, we use human genetic information to discover, develop, manufacture and commercialize medicines to treat patients with serious or life-threatening medical conditions. Today, we are among the world’s leading biotech companies, with multiple products on the market and a promising development pipeline.

598 Airport Blvd, Ste 1400 Morrisville, NC 27560 cnsvs.com

Evoke Neuroscience 11 West 25th Street, 10th Fl New York, NY 10010 evokeneuroscience.com

Evoke Neuroscience was formed in 2009 with the mission to improve diagnosis and treatment of cognitive disorders with objective, clinically meaningful and easyto-use products. Physicians use the eVox® System to assess brain health and aid in the diagnosis of memory loss and other cognitive disorders.

Exhibit Hall Passport Destination

#AANFC 29

Exhibitors Holland Hospital

Booth

342

602 Michigan Ave., LHP Administration Holland, MI 49423 hollandhospital.org Holland Hospital, located in Holland, MI, is the leading health care provider along the Lakeshore with nationally recognized quality, advanced technology and exceptional patient satisfaction. The hospital offers a full range of inpatient and outpatient services, multiple convenient locations and ready access to primary care physicians and experienced specialists. Holland Hospital has been recognized as one of America’s 50 Best hospitals and is among the region’s lowest cost providers - delivering awardwinning quality care, exceptional value and an outstanding patient experience. Since 1917, the hospital’s mission is to continually improve the health of the communities it serves in the spirit of hope, compassion, respect and dignity. For more information, visit hollandhospital.org.

Jackson & Coker

Booth

316

3000 Old Alabama Road, Suite 119-608 Alpharetta, GA 30022 jacksoncoker.com Jackson & Coker, among the most wellrecognized healthcare staffing firms in the United States, is dedicated to uniting top locum tenens physicians and advanced practitioners with the medical facilities that need them, ensuring patients have access to life-saving care in their own communities. Jackson & Coker is ranked as a Best Staffing Firm to Work For by Staffing Industry Analysts. At Jackson & Coker, “We focus on you – the patient’s true hero.” For more information, visit JacksonCoker.com.

Kaiser Permanente/ The Permanente Medical Group

Booth

225

1800 Harrison St., 7th Fl Oakland, CA 94612 physiciancareers-ncal.kaiserpermanente.org With The Permanente Medical Group, Inc., you’ll find recognition, stability, opportunity, and independence. Through our leadership in the use of advanced technology, our creation of innovative solutions and our influence on health policy and reform efforts, Kaiser Permanente is shaping the future of health care in the nation. We are proud of our physicians who work collaboratively to create a culture of healing to provide comprehensive care, achieve superior clinical outcomes and help each member maximize his or her total health. We offer our physicians a balanced call and work schedule and an excellent compensation and benefits package.

KRONUS, Inc.

Booth

108

170 S Seneca Springs Way, Suite 105 Star, ID 83669-5938 kronus.com KRONUS, a leading provider of specialized autoimmune diagnostic test kits, will be presenting information regarding our neuroimmunology-related test kits. Please take a few moments to visit our informative exhibit booth and learn more about our complete line of specialized immunoassay test kits.

30 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

Lundbeck Kyowa Kirin, Inc.

Booth

100

135 Route 202/206 Suite 6 Bedminster, NJ 07921 kyowakirin.com

Legacy Health

Booth

235

1120 NW 20th Ave Ste 111 Portland, OR 97110 legacyhealth.org Legacy Health, a nonprofit, locally owned organization based in Portland, Oregon, and serving Oregon, Southwest Washington and the Mid-Willamette Valley, is well-known for its hospitals, the only health system covering areas from Portland, Vancouver and south to Salem with multiple hospitals and a specialized children’s hospital. AAN Ad.ai 1 9/16/2019 3:19:39 PM

Booth

219

Six Parkway North Deerfield, IL 60015-2542 lundbeckus.com Lundbeck, a global pharmaceutical company based in Denmark and founded in 1915, strives for global leadership in psychiatry and neurology by improving the lives of patients. One of the world’s leading companies specializing in brain disorders, Lundbeck is focused on innovating treatments for depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.

Join the network, realize the potential NeuroNet GPO is a group purchasing organization focused on serving the needs of outpatient clinical practices and their ancillary services. GPO members partner with practices nationwide to leverage purchase power, resulting in discounted pricing on drugs and supplies. Members also gain access to valuable information and resources, which helps maximize operating performance. To learn more on how NeuroNet GPO can help your practice: Call us at (716) 558-5494 Email at info@neuronetgpo.com

BOOTH #200 Exhibit Hall Passport Destination

#AANFC 31

neuronetgpo.com

FOR THE TREATMENT OF RELAPSING FORMS OF MS

START STARTSTRONG STRONG. . STAY STAYSTRONG STRONG. .

In the 2-year DEFINE and CONFIRM pivotal trials, TECFIDERA® (dimethyl fumarate) demonstrated a 53% and 44% relative reduction in annualized relapse rate (ARR) vs placebo, respectively (0.172 vs 0.364; P<0.0001), (0.224 vs 0.401; P<0.0001)1-3

INDICATION TECFIDERA® (dimethyl fumarate) is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.

IMPORTANT SAFETY INFORMATION CONTRAINDICATIONS TECFIDERA® (dimethyl fumarate) is contraindicated in patients with known hypersensitivity to dimethyl fumarate or any of the excipients of TECFIDERA. Reactions have included anaphylaxis and angioedema. WARNING AND PRECAUTIONS Anaphylaxis and Angioedema

• TECFIDERA can cause anaphylaxis and angioedema after

the first dose or at any time during treatment. Signs and symptoms have included difficulty breathing, urticaria, and swelling of the throat and tongue. Patients should be instructed to discontinue TECFIDERA and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema

Progressive multifocal leukoencephalopathy (PML)

• PML has occurred in patients with MS treated with

TECFIDERA. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. A fatal case of PML occurred in a patient who received TECFIDERA for 4 years while enrolled in a clinical trial

• PML has occurred in the postmarketing setting in the

presence of lymphopenia (<0.8 x 109/L) persisting for more than 6 months. While the role of lymphopenia in these cases is uncertain, the majority of cases occurred in patients with lymphocyte counts <0.5 x 109/L

• At the first sign or symptom suggestive of PML, withhold

TECFIDERA and perform an appropriate diagnostic evaluation.

Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes

• Magnetic resonance imaging (MRI) findings may be apparent

before clinical signs or symptoms. Monitoring with MRI for signs consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present

Lymphopenia

• TECFIDERA may decrease lymphocyte counts. In the

MS placebo controlled trials, mean lymphocyte counts decreased by approximately 30% during the first year of treatment with TECFIDERA and then remained stable. Four weeks after stopping TECFIDERA, mean lymphocyte counts increased but did not return to baseline. Six percent (6%) of TECFIDERA patients and <1% of placebo patients experienced lymphocyte counts <0.5 x 109/L. The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with DMF or placebo, respectively. There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8 x 109/L or ≤0.5 x 109/L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5 x 109/L for 3.5 years)

• In controlled and uncontrolled clinical trials with TECFIDERA, 2% of patients experienced lymphocyte counts <0.5 x 109/L for at least six months, and in this group the majority of lymphocyte counts remained <0.5 x 109/L with continued therapy. TECFIDERA has not been studied in patients with preexisting low lymphocyte counts

• Obtain a CBC, including lymphocyte count, before initiating

treatment with TECFIDERA, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interruption of TECFIDERA in patients with lymphocyte counts less than 0.5 x 109/L persisting for more

THE #1 PRESCRIBED ORAL RMS THERAPY IN THE US SINCE SEPTEMBER 2013*

>415,000

people have been treated with TECFIDERA worldwide4

This includes clinical trial use and patients prescribed TECFIDERA

*Based on prescriptions from IMS NPATM Weekly Data (September 29, 2013–August 9, 2019)

>780,000

global patient-years of experience4

This includes clinical trial use and patients prescribed TECFIDERA

>11 Years

of combined clinical trial and real-world experience1,4

RMS=relapsing multiple sclerosis.

than six months. Given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if TECFIDERA is discontinued or interrupted due to lymphopenia. Consider withholding treatment from patients with serious infections until resolution. Decisions about whether or not to restart TECFIDERA should be individualized based on clinical circumstances Liver Injury

• Clinically significant cases of liver injury have been reported in patients treated with TECFIDERA in the postmarketing setting. The onset has ranged from a few days to several months after initiation of treatment. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Some cases required hospitalization. None of the reported cases resulted in liver failure, liver transplant, or death. However, the combination of new serum aminotransferase elevations with increased levels of bilirubin caused by drug-induced hepatocellular injury is an important predictor of serious liver injury that may lead to acute liver failure, liver transplant, or death in some patients

MOST COMMON ADVERSE REACTIONS

• TECFIDERA may cause gastrointestinal (GI) events (e.g.,

nausea, vomiting, diarrhea, abdominal pain, and dyspepsia). Four percent of TECFIDERA patients and <1% of placebo patients discontinued due to GI events. The incidence of serious GI events was 1%. The most common adverse reactions associated with TECFIDERA versus placebo are flushing (40% vs 6%) and GI events: abdominal pain (18% vs 10%), diarrhea (14% vs 11%), and nausea (12% vs 9%)

• A transient increase in mean eosinophil counts was seen during the first two months

PREGNANCY

• There is a pregnancy exposure registry that monitors

pregnancy outcomes in women exposed to TECFIDERA during pregnancy. Encourage patients to enroll by calling 1-866-810-1462 or visiting www.tecfiderapregnancyregistry.com

Please see following pages for Brief Summary of full Prescribing Information.

• Elevations of hepatic transaminases (most no greater than

Study Designs1-3 DEFINE: A 2-year, randomized, double-blind, placebo-controlled study in 1234 patients with RRMS. Secondary endpoint: ARR.

• Obtain serum aminotransferase, alkaline phosphatase, and

CONFIRM: A 2-year, multicenter, randomized, double-blind, placebo-controlled study in 1417 patients with RRMS. Primary endpoint: ARR.

3 times the upper limit of normal) were observed during controlled trials

total bilirubin levels before initiating TECFIDERA and during treatment, as clinically indicated. Discontinue TECFIDERA if clinically significant liver injury induced by TECFIDERA is suspected

Flushing

• TECFIDERA may cause flushing (e.g. warmth, redness, itching, and/or burning sensation). Forty percent of patients taking TECFIDERA reported flushing, which was mostly mild to moderate in severity. Three percent of patients discontinued TECFIDERA for flushing and <1% had serious flushing events that led to hospitalization. Taking TECFIDERA with food may reduce flushing. Alternatively, administration of non-enteric coated aspirin (up to 325mg) 30 minutes prior to dosing may reduce the incidence or severity of flushing

DEFINE=Determination of the Efficacy and Safety of Oral Fumarate in Relapsing-Remitting MS2; CONFIRM=Comparator and an Oral Fumarate in Relapsing-Remitting Multiple Sclerosis3; RRMS=relapsing-remitting multiple sclerosis. References: 1. TECFIDERA Prescribing Information, Biogen, Cambridge, MA. 2. Gold R, et al. N Engl J Med. 2012;367(24):2362. 3. Fox RJ, et al. N Engl J Med. 2012;367(12):1087-1097. 4. Data on file, Biogen.

To get started, simply fill out a Start Form at

www.tecfiderahcp.com

Tecfidera® (dimethyl fumarate) delayed-release capsules, for oral use Brief Summary of Full Prescribing Information 1 INDICATIONS AND USAGE TECFIDERA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. 2 DOSAGE AND ADMINISTRATION 2.1 Dosing Information The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Temporary dose reductions to 120 mg twice a day may be considered for individuals who do not tolerate the maintenance dose. Within 4 weeks, the recommended dose of 240 mg twice a day should be resumed. Discontinuation of TECFIDERA should be considered for patients unable to tolerate return to the maintenance dose. The incidence of flushing may be reduced by administration of TECFIDERA with food. Alternatively, administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to TECFIDERA dosing may reduce the incidence or severity of flushing [see Clinical Pharmacology (12.3)]. TECFIDERA should be swallowed whole and intact. TECFIDERA should not be crushed or chewed and the capsule contents should not be sprinkled on food. TECFIDERA can be taken with or without food. 2.2 Blood Tests Prior to Initiation of Therapy Obtain a complete blood cell count (CBC) including lymphocyte count before initiation of therapy [see Warnings and Precautions (5.3)]. Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels prior to treatment with TECFIDERA [see Warnings and Precautions (5.4)]. 3 DOSAGE FORMS AND STRENGTHS TECFIDERA is available as hard gelatin delayed-release capsules containing 120 mg or 240 mg of dimethyl fumarate. The 120 mg capsules have a green cap and white body, printed with “BG-12 120 mg” in black ink on the body. The 240 mg capsules have a green cap and a green body, printed with “BG-12 240 mg” in black ink on the body. 4 CONTRAINDICATIONS TECFIDERA is contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of TECFIDERA. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.1)]. 5 WARNINGS AND PRECAUTIONS 5.1 Anaphylaxis and Angioedema TECFIDERA can cause anaphylaxis and angioedema after the first dose or at any time during treatment. Signs and symptoms have included difficulty breathing, urticaria, and swelling of the throat and tongue. Patients should be instructed to discontinue TECFIDERA and seek immediate medical care should they experience signs and symptoms of anaphylaxis or angioedema. 5.2 Progressive Multifocal Leukoencephalopathy Progressive multifocal leukoencephalopathy (PML) has occurred in patients with MS treated with TECFIDERA. PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. A fatal case of PML occurred in a patient who received TECFIDERA for 4 years while enrolled in a clinical trial. During the clinical trial, the patient experienced prolonged lymphopenia (lymphocyte counts predominantly <0.5x109/L for 3.5 years) while taking TECFIDERA [see Warnings and Precautions (5.3)]. The patient had no other identified systemic medical conditions resulting in compromised immune system function and had not previously been treated with natalizumab, which has a known association with PML. The patient was also not taking any immunosuppressive or immunomodulatory medications concomitantly. PML has also occurred in the postmarketing setting in the presence of lymphopenia (<0.8x109/L) persisting for more than 6 months. While the role of lymphopenia in these cases is uncertain, the majority of cases occurred in patients with lymphocyte counts <0.5x109/L. At the first sign or symptom suggestive of PML, withhold TECFIDERA and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. MRI findings may be apparent before clinical signs or symptoms. Cases of PML, diagnosed based on MRI findings and the detection of JCV DNA in the cerebrospinal fluid in the absence of clinical signs or symptoms specific to PML, have been reported in patients treated with other MS medications associated with PML. Many of these patients subsequently became symptomatic with PML. Therefore, monitoring with MRI for signs that may be consistent with PML may be useful, and any suspicious findings should lead to further investigation to allow for an early diagnosis of PML, if present. Lower PML-related mortality and morbidity have been reported following discontinuation of another MS medication associated with PML in patients with PML who were initially asymptomatic compared to patients with PML who had characteristic clinical signs and symptoms at diagnosis. It is not known whether these differences are due to early detection and discontinuation of MS treatment or due to differences in disease in these patients. 5.3 Lymphopenia TECFIDERA may decrease lymphocyte counts. In the MS placebo controlled trials, mean lymphocyte counts decreased by approximately 30% during the first year of treatment with TECFIDERA and then remained stable. Four weeks after stopping TECFIDERA, mean lymphocyte counts increased but did not return to baseline. Six percent (6%) of TECFIDERA patients and <1% of placebo patients experienced lymphocyte counts <0.5x109/L (lower limit of normal 0.91x109/L). The incidence of infections (60% vs 58%) and serious infections (2% vs 2%) was similar in patients treated with TECFIDERA or placebo, respectively. There was no increased incidence of serious infections observed in patients with lymphocyte counts <0.8x109/L or ≤0.5x109/L in controlled trials, although one patient in an extension study developed PML in the setting of prolonged lymphopenia (lymphocyte counts predominantly <0.5x109/L for 3.5 years) [see Warnings and Precautions (5.2)]. In

controlled and uncontrolled clinical trials, 2% of patients experienced lymphocyte counts <0.5x109/L for at least six months, and in this group the majority of lymphocyte counts remained <0.5x109/L with continued therapy. TECFIDERA has not been studied in patients with pre-existing low lymphocyte counts. Obtain a CBC, including lymphocyte count, before initiating treatment with TECFIDERA, 6 months after starting treatment, and then every 6 to 12 months thereafter, and as clinically indicated. Consider interruption of TECFIDERA in patients with lymphocyte counts less than 0.5x109/L persisting for more than six months. Given the potential for delayed recovery of lymphocyte counts, continue to obtain lymphocyte counts until their recovery if TECFIDERA is discontinued or interrupted due to lymphopenia. Consider withholding treatment from patients with serious infections until resolution. Decisions about whether or not to restart TECFIDERA should be individualized based on clinical circumstances. 5.4 Liver Injury Clinically significant cases of liver injury have been reported in patients treated with TECFIDERA in the postmarketing setting. The onset has ranged from a few days to several months after initiation of treatment with TECFIDERA. Signs and symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal and elevation of total bilirubin to greater than 2-fold the upper limit of normal have been observed. These abnormalities resolved upon treatment discontinuation. Some cases required hospitalization. None of the reported cases resulted in liver failure, liver transplant, or death. However, the combination of new serum aminotransferase elevations with increased levels of bilirubin caused by drug-induced hepatocellular injury is an important predictor of serious liver injury that may lead to acute liver failure, liver transplant, or death in some patients. Elevations of hepatic transaminases (most no greater than 3 times the upper limit of normal) were observed during controlled trials [see Adverse Reactions (6.1)]. Obtain serum aminotransferase, alkaline phosphatase (ALP), and total bilirubin levels prior to treatment with TECFIDERA and during treatment, as clinically indicated. Discontinue TECFIDERA if clinically significant liver injury induced by TECFIDERA is suspected. 5.5 Flushing TECFIDERA may cause flushing (e.g., warmth, redness, itching, and/or burning sensation). In clinical trials, 40% of TECFIDERA treated patients experienced flushing. Flushing symptoms generally began soon after initiating TECFIDERA and usually improved or resolved over time. In the majority of patients who experienced flushing, it was mild or moderate in severity. Three percent (3%) of patients discontinued TECFIDERA for flushing and <1% had serious flushing symptoms that were not life-threatening but led to hospitalization. Administration of TECFIDERA with food may reduce the incidence of flushing. Alternatively, administration of non-enteric coated aspirin (up to a dose of 325 mg) 30 minutes prior to TECFIDERA dosing may reduce the incidence or severity of flushing [see Dosing and Administration (2.1) and Clinical Pharmacology (12.3)]. 6 ADVERSE REACTIONS The following important adverse reactions are described elsewhere in labeling: Anaphylaxis and Angioedema (5.1), Progressive multifocal leukoencephalopathy (5.2), Lymphopenia (5.3), Liver Injury (5.4), Flushing (5.5) [see Warnings and Precautions]. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The most common adverse reactions (incidence ≥10% and ≥2% more than placebo) for TECFIDERA were flushing, abdominal pain, diarrhea, and nausea. Adverse Reactions in Placebo-Controlled Trials In the two well-controlled studies demonstrating effectiveness, 1529 patients received TECFIDERA with an overall exposure of 2244 person-years [see Clinical Studies (14)]. The adverse reactions presented in the table below are based on safety information from 769 patients treated with TECFIDERA 240 mg twice a day and 771 placebo-treated patients. Table 1: Adverse Reactions in Study 1 and 2 reported for TECFIDERA 240 mg BID at ≥2% higher incidence than placebo TECFIDERA N=769 %

Placebo N=771 %

Flushing

Abdominal pain

Diarrhea

Nausea

Vomiting

Pruritus

Rash

Albumin urine present

Erythema

Dyspepsia

Aspartate aminotransferase increased

Lymphopenia

Gastrointestinal TECFIDERA caused GI events (e.g., nausea, vomiting, diarrhea, abdominal pain, and dyspepsia). The incidence of GI events was higher early in the course of treatment (primarily in month 1) and usually decreased over time in patients treated with TECFIDERA compared with placebo. Four percent (4%) of patients treated with TECFIDERA and less than 1% of placebo patients discontinued due to gastrointestinal events. The incidence of serious GI events was 1% in patients treated with TECFIDERA. Hepatic Transaminases An increased incidence of elevations of hepatic transaminases in patients treated with TECFIDERA was seen primarily during the first six months of treatment, and most patients with elevations had levels <3 times the upper limit of normal (ULN) during controlled trials. Elevations of alanine aminotransferase and aspartate aminotransferase to ≥3 times the ULN occurred in a small number of patients treated with both TECFIDERA and placebo and were balanced between groups. There were no elevations in transaminases ≥3 times the ULN with concomitant elevations in total bilirubin >2 times the ULN. Discontinuations due to elevated hepatic transaminases were <1% and were similar in patients treated with TECFIDERA or placebo. Eosinophilia A transient increase in mean eosinophil counts was seen during the first 2 months of therapy. Adverse Reactions in Placebo-Controlled and Uncontrolled Studies In placebo-controlled and uncontrolled clinical studies, a total of 2513 patients have received TECFIDERA and been followed for periods up to 4 years with an overall exposure of 4603 person-years. Approximately 1162 patients have received more than 2 years of treatment with TECFIDERA. The adverse reaction profile of TECFIDERA in the uncontrolled clinical studies was consistent with the experience in the placebo-controlled clinical trials. 6.2 Post Marketing Experience The following adverse reaction has been identified during post approval use of TECFIDERA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Liver function abnormalities (elevations in transaminases ≥3 times ULN with concomitant elevations in total bilirubin >2 times ULN) have been reported following TECFIDERA administration in post marketing experience [See Warnings and Precautions (5.4)]. 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Pregnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to TECFIDERA during pregnancy. Encourage patients to enroll by calling 1-866-810-1462 or visiting www.tecfiderapregnancyregistry.com. Risk Summary There are no adequate data on the developmental risk associated with the use of TECFIDERA in pregnant women. In animals, adverse effects on offspring survival, growth, sexual maturation, and neurobehavioral function were observed when dimethyl fumarate (DMF) was administered during pregnancy and lactation at clinically relevant doses. [see data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. The background risk of major birth defects and miscarriage for the indicated population is unknown. Data Animal Data In rats administered DMF orally (25, 100, 250 mg/kg/day) throughout organogenesis, embryofetal toxicity (reduced fetal body weight and delayed ossification) were observed at the highest dose tested. This dose also produced evidence of maternal toxicity (reduced body weight). Plasma exposure (AUC) for monomethyl fumarate (MMF), the major circulating metabolite, at the no-effect dose is approximately three times that in humans at the recommended human dose (RHD) of 480 mg/day. In rabbits administered DMF orally (25, 75, and 150 mg/kg/day) throughout organogenesis, embryolethality and decreased maternal body weight were observed at the highest dose tested. The plasma AUC for MMF at the no-effect dose is approximately 5 times that in humans at the RHD. Oral administration of DMF (25, 100, and 250 mg/kg/day) to rats throughout organogenesis and lactation resulted in increased lethality, persistent reductions in body weight, delayed sexual maturation (male and female pups), and reduced testicular weight at the highest dose tested. Neurobehavioral impairment was observed at all doses. A no-effect dose for developmental toxicity was not identified. The lowest dose tested was associated with plasma AUC for MMF lower than that in humans at the RHD. 8.2 Lactation Risk Summary There are no data on the presence of DMF or MMF in human milk. The effects on the breastfed infant and on milk production are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for TECFIDERA and any potential adverse effects on the breastfed infant from the drug or from the underlying maternal condition. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. 8.5 Geriatric Use Clinical studies of TECFIDERA did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. 10 OVERDOSE Cases of overdose with TECFIDERA have been reported. The symptoms described in these cases were consistent with the known adverse event profile of TECFIDERA.

There are no known therapeutic interventions to enhance elimination of TECFIDERA nor is there a known antidote. In the event of overdose, initiate symptomatic supportive treatment as clinically indicated. 17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information) Dosage Inform patients that they will be provided two strengths of TECFIDERA when starting treatment: 120 mg capsules for the 7 day starter dose and 240 mg capsules for the maintenance dose, both to be taken twice daily. Inform patients to swallow TECFIDERA capsules whole and intact. Inform patients to not crush, chew, or sprinkle capsule contents on food. Inform patients that TECFIDERA can be taken with or without food [see Dosage and Administration (2.1)]. Anaphylaxis and Angioedema Advise patients to discontinue TECFIDERA and seek medical care if they develop signs and symptoms of anaphylaxis or angioedema [see Warnings and Precautions (5.1)]. Progressive Multifocal Leukoencephalopathy Inform patients that progressive multifocal leukoencephalopathy (PML) has occurred in patients who received TECFIDERA. Inform the patient that PML is characterized by a progression of deficits and usually leads to death or severe disability over weeks or months. Instruct the patient of the importance of contacting their doctor if they develop any symptoms suggestive of PML. Inform the patient that typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes [see Warnings and Precautions (5.2)]. Lymphocyte Counts Inform patients that TECFIDERA may decrease lymphocyte counts. A blood test should be obtained before they start therapy. Blood tests are also recommended after 6 months of treatment, every 6 to 12 months thereafter, and as clinically indicated [see Warnings and Precautions (5.3), Adverse Reactions (6.1)]. Liver Injury Inform patients that TECFIDERA may cause liver injury. Instruct patients treated with TECFIDERA to report promptly any symptoms that may indicate liver injury, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice. A blood test should be obtained before patients start therapy and during treatment, as clinically indicated [see Warnings and Precautions (5.4)]. Flushing and Gastrointestinal (GI) Reactions Flushing and GI reactions (abdominal pain, diarrhea, and nausea) are the most common reactions, especially at the initiation of therapy, and may decrease over time. Advise patients to contact their healthcare provider if they experience persistent and/or severe flushing or GI reactions. Advise patients experiencing flushing that taking TECFIDERA with food or taking a non-enteric coated aspirin prior to taking TECFIDERA may help [see Adverse Reactions (6.1)]. Pregnancy and Pregnancy Registry Instruct patients that if they are pregnant or plan to become pregnant while taking TECFIDERA they should inform their physician. Encourage patients to enroll in the TECFIDERA Pregnancy Registry if they become pregnant while taking TECFIDERA. [see Use in Specific Populations (8.1)]. 41347-10 Manufactured for: Biogen Cambridge, MA 02142 TECFIDERA is a trademark of Biogen. © 2013-2017 Biogen 7/2019

Exhibitors Marshfield Clinic Health System

Booth

336

1000 N Oak Ave Marshfield, WI 54449 marshfieldclinic.org

Booth

334

Memorial Healthcare System is one of the largest public healthcare systems in the United States. A national leader in quality care and patient satisfaction, Memorial has ranked 11 times since 2008 on nationally recognized lists of great places to work. Memorial is located in South Florida, a region with a high quality of life – including year-round summer weather, exciting multiculturalism and no state income tax – that attracts new residents from all over the country and around the world.

314

3050 Superior Dr NW Rochester, MN 55901

Midland Health

Our laboratories, led by clinical neurologists, offer a highly specialized test menu that provides answers for everything from the simplest to the most complex cases. These neurologists are experts in their field and available seven days a week to help fellow physicians interpret each evaluation to provide clinically actionable answers, not just results.

McKesson

Booth

3107 Stirling Road, Suite 101 Hollywood, FL 33312 memorialphysician.com

Marshfield Clinic Health System physicians and staff serve more than 360,000 unique patients each year through accessible, high quality health care, research and education. With 700+ physicians in 86 medical specialties and subspecialties as well as over 10,000 employees in 58 clinical locations in 34 Wisconsin communities, Marshfield Clinic is nationally recognized for innovative practices and quality care.

Mayo Clinical Laboratories

Memorial Healthcare System

Booth

401

One Post St San Francisco, CA 94105 mckesson.com

Booth

340

400 Rosalind Redfern Grover Parkway Midland, TX 79701 midlandhealth.org Midland Health believes the health of a community extends far beyond hospital walls. And we are committed to leading our community to be the healthiest in Texas. That’s why we’ve teamed up with area healthcare partners to create Midland Health. Working together, we can make a profound and lasting impact on our community by improving the health of our people. Midland Health consists of Midland Memorial Hospital a 474 bed hospital and Multi-Specialty group 13 affiliated clinics and Partner Organizations.

McKesson provides neurologists the freedom to focus on care through solutions and services such as the Onmark® GPO, Lynx® for inventory management, managed care and revenue cycle advisors, and Intrafusion® infusion management. For more information, visit www.mckesson.com/neurology.

36 2019 AAN APP Pre-conference & Fall Conference Exhibit & On-site Guide

NeuroNet GPO

Booth

200

3980 Sheridan Drive Amherst, NY 14226 neuronetgpo.com NeuroNet GPO is a group purchasing organization focused on serving the needs of outpatient clinical practices and their ancillary services. GPO members partner with practices nationwide to leverage purchase power, resulting in discounted pricing on drugs and supplies. Members also gain access to valuable information and resources, which helps maximize operating performance.

Novartis Pharmaceuticals

Booth

132

One Health Plaza East Hanover, NJ 07936 novartis.com Novartis is reimagining medicine to improve and extend people’s lives. We use innovative science and digital technologies to create transformative treatments. Novartis products reach more than 750 million people globally and we are finding innovative ways to expand access to our medicines. About 105,000 people of more than 140 nationalities work at Novartis. www.novartis.com.

PatientPoint

Booth

302

5901 E. Galbraith Road, Suite R1000 Cincinnati, OH 45236 patientpoint.com

solutions are proven to deliver improved health outcomes and an enhanced patient experience. Learn more at patientpoint.com.

Penn State Health

Booth

324

Department of Human Resources, MC CA230, Post Office Box 850, Hershey, PA 17033 pennstatehealth.org Penn State Health is a multi-hospital health system serving patients and communities across central Pennsylvania. The system includes Penn State Health St. Joseph Medical Center in Reading, Pa., Penn State Health Milton S. Hershey Medical Center, Penn State Children’s Hospital, Penn State Cancer Institute, and Penn State Health Rehabilitation Hospital (jointly owned), based in Hershey, Pa., as well as more than 1,300 physicians and direct care providers at 78 medical office locations. The system also has jointly owned health care providers, including Hershey Outpatient Surgery Center, Hershey Endoscopy Center, Horizon Home Healthcare and the Pennsylvania Psychiatric Institute. Penn State Health shares an integrated strategic plan and operations with Penn State College of Medicine, the University’s medical school.

PatientPoint® is a patient engagement solutions company passionately committed to making every doctor-patient engagement better™. Harnessing the power of digital and mobile technology, our omnichannel platform helps healthcare providers more effectively educate and empower patients, caregivers and staff across care settings. PatientPoint Exhibit Hall Passport Destination

#AANFC 37

At Adamas our purpose is to make everyday life significantly better for people affected by neurological disorders.

For more information, please visit our website at www.adamaspharma.com

Portneuf Medical Center

Booth

341

777 Hospital Way Pocatello, ID 83201 portneuf.org

Booth

231

353 Fairmont Blvd Rapid City, SD 57701 regionalhealth.org We are the largest health care system in western South Dakota. Headquartered in Rapid City our system consists of 5 hospitals, 24 clinics and employs nearly 5000 physicians & caregivers. Our family friendly community is located in the foothills of the beautiful Black Hills which boasts a myriad of outdoor activities including hiking, camping, boating fishing & hunting.

RosmanSearch, Inc.

Booth

207

50 Binney Street Cambridge, MA 02142-1108 sanofigenzyme.com

Portneuf Medical Center, part of Ardent Health Services, is located in the beautiful hills of Southern Idaho. Just on the edge of the Snake River Plain, there’s an adventure for everyone! Come and explore what Idaho has to offer!

Regional Health

Sanofi Genzyme

Booth

227

30799 Pinetree Road, #250 Pepper Pike, OH 44124 rosmansearch.com RosmanSearch, Inc. is a targeted physician recruitment firm that serves the needs of the neurosurgical and neurological communities. Our mission is to place quality physicians with quality practices, academic departments and hospitals nationwide. We are the only search firm in the country with dedicated teams specializing solely in neurosurgery and neurology. Our mission is to be the best, the most expert, and the one that is known for quality advice and real expertise—every time! Exhibit Hall Passport Destination

Sanofi Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years.

SoutheastHEALTH

Booth

229

1701 Lacey Street Cape Girardeau, MO 63701 sehealth.org SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital in Cape Girardeau, MO, which provides a regional system of healthcare services throughout a multi-state region. SoutheastHEALTH serves patients in southeast Missouri, as well as residents in parts of southern Illinois, western Kentucky and northern Arkansas.

Spartanburg Regional

Booth

237

101 E Wood Street Spartanburg, SC 29303 spartanburgregional.com Spartanburg Regional Healthcare System (SRHS) offers a full spectrum of services through six hospital campuses: Spartanburg Medical Center, Spartanburg Medical Center—Mary Black Campus, Pelham Medical Center, Cherokee Medical Center, Spartanburg Hospital for Restorative Care and Union Medical Center. SRHS also includes Ellen Sagar Nursing Center and Woodruff Manor. Also part of the healthcare system is the multidisciplinary Medical Group of the Carolinas, which has more than 400 physicians across Upstate South Carolina and western North Carolina.

#AANFC 39

We’re Hiring Neurology Providers PS+D: Your clinical career navigator in health care. In service to healthier communities, we forge last-ing partnerships between providers and purpose-driven health systems in diverse communities across the country.

Where would you like to go? With 800+ provider career opportunities at some of the nation’s top health systems, we can navigate you to the perfect practice for a lasting career. + 80+ Recruitment Professionals + 1000+ Providers Hired Annually + Millions of Patients Cared For

Let’s Talk! We are PS+D, here to help you realize your practice potential. Phone: 844.874.7742 Email: LetsTalk@psdrecruit.org

Find your perfect practice at psdrecruit.org

Representing purpose-driven health systems across the nation, including: AND MANY OTHERS

Spectrum Health Lakeland

Booth

437

1234 Napier Ave St. Joseph, MI 49085 spectrumhealthlakeland.org/ Spectrum Health Lakeland is a non-profit, community-owned health system serving southwest Michigan and northern Indiana. We offer a full continuum of care and wellness services including three hospitals, an outpatient surgery center, a cancer center, and 41 physician practices. Lakeland is a division of Spectrum Health with 31,000 compassionate professionals, 4,200 medical staff experts, 3,200 committed volunteers and a health plan serving 1 million members. For the second time, Spectrum Health Lakeland was recognized as a 15 Top Health System by IBM Watson Health™.

St. Elizabeth Physicians

Booth

330

1360 Dolwick Drive Erlanger, KY 41018 stedocs.com Come join a growing, well-respected group with the full support of our award-winning hospital system, St. Elizabeth Healthcare. St. Elizabeth Physicians offers a competitive compensation and benefits package. Working at St. Elizabeth Physicians allows you to enjoy Kentucky’s natural charm while all metropolitan greater Cincinnati offers is just minutes away. Northern Kentucky is on the banks of the Ohio River and boasts affordable costs of living, award-winning schools, colleges and professional sports, exceptional fine arts and the distinction of being sixth in the nation for its number of Fortune 500 Company headquarters. The Cincinnati area was recently named one of the trendiest cities in the nation by Realtor. com. We are a mission and values driven organization, focused on patient-centered care, accountability, community, innovation, Exhibit Hall Passport Destination

teamwork and excellence. St. Elizabeth is a regional healthcare provider continually recognized as one of the nation’s best. We are also a proud member of the Mayo Clinic Care Network. This network provides access to proven protocols, eConsults and unparalleled experience. It supports our mission to ensure our patients receive comprehensive and compassionate care – anywhere.

Strongbridge Biopharma

Booth

300

900 Northbrook Blvd. Suite 200 Trevose, PA 19053 strongbridgebio.com Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on therapies for rare diseases. Strongbridge has the only FDAapproved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis (PPP). PPP is a group of rare hereditary disorders that causes potentially severe episodes of muscle weakness and/or paralysis.

Summa Health

Booth

332

525 E. Market St Akron, OH 44304 summahealth.org Summa Health – headquartered in Akron, Ohio – is one of the largest integrated Healthcare Delivery Systems in the state. With 2 hospitals and 20+ health centers, Summa Health provides access to care throughout the region.

#AANFC 41

NEUROLOGY Spartanburg Medical Center (SMC) is seeking a BC/BE neurologist to join an expanding neurology program in a onehundred percent outpatient practice. SMC is a stroke-certified trauma center, tertiary referral center and community teaching hospital for the upstate. Highlights of the opportunity include:

schools, a growing regional healthcare

• Monday – Friday; 8 – 5

system, and a vibrant downtown. Just

• Call 1:3; shared with NP

an hour from the Blue Ridge Mountains

• Full scope neurology practice

and a few hours from the ocean,

• Neurohospitalist and telemedicine handle hospital consults • Procedures: – Lumbar punctures

recreational opportunities are endless. Come find out why so many want to live here in the upstate!

– EMG

Contact:

– Botox

Kristin Baker, Senior Physician Recruiter

• Paid malpractice to include tail coverage

864-560-6331 • kbaker@srhs.com SpartanburgRegional.com

• Competitive salary package • $6,000 CME annually • Attractive retirement options The Upstate is an affordable, familyfriendly community with highly rated

Spartanburg, South Carolina

Sunovion Pharmaceuticals Inc.

Booth

106

Booth

217

109 Professional Park Dr., Suite 200 Charlotte, NC 28117 truelearn.com

84 Waterford Dr Marlborough, MA 01752 sunovion.com

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. The Company has charted new paths to lifetransforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological, and respiratory conditions.

Supernus Pharmaceuticals, Inc.

TrueLearn

Booth

215

1550 E Gude Drive Rockville, MD 20850-1339 supernus.com

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extendedrelease topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in ADHD patients and SPN-812 for the treatment of ADHD.

Exhibit Hall Passport Destination

Used by 600+ residency programs, TrueLearn is an online learning platform offering access to next generation Qbanks: SmartBanks. SmartBanks leverage evidenced based learning science, helping residents become better thinkers, learners, and testers. Neurology Residents can prepare for InTraining and Board Certification Exams with hundreds of questions crafted by physicians, mapped directly to exam blueprints. Programs can enhance overall outcomes by measuring and tracking exam readiness early on.

Upsher-Smith Laboratories, Inc.

Booth

413

6701 Evenstad Dr N Maple Grove, MN 55369-6026 upsher-smith.com Upsher-Smith Laboratories, LLC is a trusted U.S. pharmaceutical company that has strived to deliver quality, affordable medications for nearly a century. In June 2017, Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd, a large publicly traded generics company in Japan that shares a similar philosophy of always putting patients first. For more information, visit www.upsher-smith.com.

#AANFC 43

Neurologist Opportunities

Neurologists with expertise in Epilepsy, Movement Disorders, Neuromuscular and Vascular Neurology are invited to apply for open physician-scientist positions at Penn State Health Milton S. Hershey Medical Center, which is the academic medical center of The Penn State College of Medicine. This search represents part of a major institutional commitment to expansion of the neurosciences. The successful candidate will join the collegial faculty of Penn State Neurology, which is in an exciting period of growth under the leadership of the Chair, Krish Sathian, MBBS, PhD. Faculty rank will be commensurate with experience. Leadership opportunities are available to those with relevant experience. FOR ADDITIONAL INFORMATION, PLEASE CONTACT: Patty Shipton, FASPR, Physician Recruiter at pshipton@pennstatehealth.psu.edu or 717-531-4703.

IDEAL CANDIDATES WILL HAVE THE FOLLOWING:

• Medical degree – MD, DO, or foreign equivalent • BC/BE in Neurology and relevant fellowship training or foreign equivalent • Relevant clinical interest and expertise • Excellent patient care abilities and interest in teaching WHAT ELSE CAN YOU EXPECT?

AS A MEMBER OF THE DEPARTMENT OF NEUROLOGY YOU WILL BE ASSOCIATED WITH:

• An outstanding Neurology program with a national reputation • A highly collaborative culture • Interaction with dynamic clinicians across all neuroscience-related departments and participation in innovative educational approaches

• Competitive compensation • Generous benefits, including relocation assistance The Penn State Health Milton S. Hershey Medical Center is committed to affirmative action, equal opportunity and the diversity of its workforce. EOE-AA-M/F/D/V. All individuals (including current employees) selected for a position will undergo a background check appropriate for the position’s responsibilities.

Wolters Kluwer

Booth

405

Two Commerce Sq, 2001 Market Street Philadelphia, PA 19103 lww.com Wolters Kluwer Health is a global provider of information, business intelligence and point-of-care solutions for the healthcare industry . Brands include Lippincott Williams & Wilkins, a leading international publisher of medical books, electronic media and journals and the official publisher of American Academy of Neurology. We proudly offer specialized publications and software for physicians, nurses, students and clinicians. Please visit our booth to browse our comprehensive product line.

WVU Medicine Rockefeller Neuroscience Institute

Booth

disorders. WVU is certified as a Primary Stroke Center and Level IV Epilepsy Center. For inquiries about opportunities, contact Kelli Piccirillo, Sr. Physician Recruiter, at piccirillok@wvumedicine.org or Dr. David Watson, Chairman, at dwatson@hsc.wvu.edu.

328

1 Medical Center Drive, PO Box 8291 Morgantown, WV 26506 wvumedicine.org The Department of Neurology at West Virginia University School of Medicine and the Rockefeller Neuroscience Institute, led by Dr. Ali Rezai, is expanding to include the clinical, research, and academic missions of Neurosurgery, Neurology, and Behavioral Medicine and Psychiatry, among others. The Institute will spearhead efforts to develop innovative solutions for West Virginians and those across the world with neurological and psychiatric conditions ranging from Alzheimer’s to Parkinson’s; autism to stroke; and paralysis to chronic pain, addictions, and traumatic brain injury. The Department of Neurology offers patients a full spectrum of innovative therapies for neurologic disease, including stroke, epilepsy, neuromuscular diseases, headache, immunology, and movement Exhibit Hall Passport Destination

#AANFC 45

SEE YOU NEXT YEAR! April 25-May 1, 2020

Toronto, Canada

July 17-19, 2020

Minneapolis, MN

October 9-11, 2020

Caesars Palace Las Vegas NEW LOCATION!

Stay tuned for announcements about our NEW regional conference for Advanced Practice Providers in 2020.